The Effect of Trimetazidine Added to Pharmacological Treatment on All-Cause Mortality in Patients with Systolic Heart Failure
- 27 March 2015
- journal article
- research article
- Published by S. Karger AG in Cardiology
- Vol. 131 (1), 22-29
- https://doi.org/10.1159/000375288
Abstract
The anti-ischemic agent trimetazidine (TMZ) added to pharmacological treatment appears to have positive effects on cardiac parameters of patients with heart failure (HF) as a result of specific antioxidant properties. Objectives: We aimed to verify whether the marked improvement provided by TMZ in echocardiographic and clinical parameters was likely to translate into reduced all-cause mortality in systolic HF patients. Methods: Meta-analysis of available published prospective randomized controlled trial (RCT) data (1967-2014) retrieved from PubMed, Web of Science and Cochrane Collaboration. Results: A total of 326 patients from 3 RCTs were analyzed: 164 who received TMZ on top of pharmacological HF therapy and 162 controls. Study durations ranged from 12 to 48 months. The analysis had no publication bias and the studies were homogeneous (p = 0.442, I2 = 0). The results show a significant effect of TMZ on the reduction of all-cause mortality (RR = 0.283, p < 0.0001). The rate of events attributable to the drug was lower with TMZ than it was among control patients. Conclusion: This meta-analysis suggests that in patients with HF, TMZ given as an add-on therapy is likely to provide a protective effect, reduce all-cause mortality and increase event-free survival, and could be an effective and useful adjunct to our armamentarium for the treatment of HF patients.Keywords
This publication has 32 references indexed in Scilit:
- Effect of partial fatty acid oxidation inhibition with trimetazidine on mortality and morbidity in heart failure: Results from an international multicentre retrospective cohort studyInternational Journal of Cardiology, 2013
- Efficacy Comparison of Trimetazidine with Therapeutic Alternatives in Stable Angina Pectoris: A Network Meta-AnalysisCardiology, 2011
- Modulating fatty acid oxidation in heart failureCardiovascular Research, 2011
- The Failing Heart — An Engine Out of FuelThe New England Journal of Medicine, 2007
- A Randomized Clinical Trial of Trimetazidine, a Partial Free Fatty Acid Oxidation Inhibitor, in Patients With Heart FailureJournal of the American College of Cardiology, 2006
- Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failureEuropean Heart Journal, 2006
- Trimetazidine for stable anginaPublished by Wiley ,2005
- Myocardial Substrate Metabolism in the Normal and Failing HeartPhysiological Reviews, 2005
- Assessment of Anti-Ischemic and Antianginal Effect at Trough Plasma Concentration and Safety of Trimetazidine MR 35mg in Patients with Stable Angina PectorisAmerican Journal of Cardiovascular Drugs, 2003
- TrimetazidineDrugs, 1999